Side-by-side comparison

NVO vs DHR — Side-by-side comparison

DHR screens cheaper on EV/FCF, DHR has the higher ROIC, DHR has grown revenue faster over five years, and DHR has the cleaner balance sheet by net debt / EBITDA.

NVO

Novo Nordisk A S

Price

$44.96

Market cap

$305.8B

Day %

N/A

DHR

Danaher Corp.

Price

$172.00

Market cap

$141.3B

Day %

N/A

Peer Comparison

Target stock against 1 market-cap comparable peer.

Heat map: red worst to green best


NVO Target	Novo Nordisk A S	$305.8B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DHR	Danaher Corp.	$141.3B	34.1x	29.5x	5.1%	2.0%	21.4%	59.1%	2.5x	N/A

NVO implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

N/A

FCF yield

N/A

5Y rev CAGR

N/A

DHR implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

29.5x

FCF yield

3.7%

5Y rev CAGR

2.0%

5Y indexed stock chart

Static Recharts view indexed to 100 from available annual per-share data.

Quality Scorecard

Build-time composite score for NVO.

Grade F

/ 100

Quality Scorecard

Build-time composite score for DHR.

Grade C

/ 100